<DOC>
	<DOCNO>NCT01144572</DOCNO>
	<brief_summary>The purpose study evaluate quality life ( Qol ) postmenopausal HR ( + ) EBC patient adjuvant AIs treatment term : change trial outcome index ( TOI ) FACT-B questionnaire baseline 24 month . This study recruit approximately 500 patient 21 site China . The patient postmenopausal HR ( + ) EBC patient already start adjuvant AIs treatment within 7 day .</brief_summary>
	<brief_title>Quality Life Chinese Postmenopausal HR ( + ) Early Breast Cancer ( EBC ) Patients During Adjuvant Aromatase Inhibitors ( AIs ) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Postmenopausal woman â‰¤ 70 year old , histologically proven HR ( + ) early breast cancer . Undergoing upfront AIs adjuvant treatment within 7 day . Patients disagree participate study Patients , whatever reason ( eg , confusion , infirmity ) , unlikely comply trial requirement . The AIs approve SFDA indication upfront adjuvant endocrine therapy early breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Quality Life</keyword>
	<keyword>postmenopausal HR ( + )</keyword>
	<keyword>Early Breast Cancer</keyword>
	<keyword>adjuvant AI treatment</keyword>
	<keyword>Quality Life Chinese postmenopausal HR ( + ) EBC patient adjuvant Aromatase Inhibitors ( AIs ) treatment</keyword>
</DOC>